[en] BACKGROUND: Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban. METHODS: With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 mL/min, weight ≤60 kg, and/or use of strong p-glycoprotein inhibitors) of patients from Belgium and the Netherlands (BeNe) with those from other European countries (OEC). RESULTS: Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA(2)DS(2)-VASc (mean: 2.8 vs 3.2) and HAS-BLED scores (mean: 2.4 vs 2.6). Patients from BeNe less often had hypertension (61.6% vs 80.4%), and/or diabetes mellitus (17.3% vs 23.1%) than patients from OEC. Moreover, relatively fewer patients in BeNe were prescribed the reduced dose of 30 mg edoxaban (14.8%) than in OEC (25.4%). Overall, edoxaban was dosed according to label in 83.1% of patients. Yet, 30 mg edoxaban was prescribed in the absence of any dose reduction criteria in 36.9% of 30 mg users (5.5% of all patients) in BeNe compared with 35.5% (9.0% of all patients) in OEC. CONCLUSION: There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation. TRIAL REGISTRATION: NCT02944019; Date of registration: October 24, 2016.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
de Vries, Tim A C ; Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands. ; Department of Cardiology, Amsterdam Medical Centres/University of Amsterdam
Hemels, Martin E W ; Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands. ; Department of Cardiology, Radboud University Medical Centre, Nijmegen, The
Cools, Frank ; Department of Cardiology, General Hospital Klinieken Noord-Antwerpen, Brasschaat
Crijns, Harry J G M ; Department of Cardiology, Maastricht University Medical Centre, Maastricht, The
Yperzeele, Laetitia ; Department of Neurosurgery, University Hospital Antwerp, Antwerp, Belgium.
Vanacker, Peter; Department of Neurosurgery, University Hospital Antwerp, Antwerp, Belgium. ; Department of Neurology, General Hospital Groeninge, Kortrijk, Belgium.
Blankoff, Ivan; Department of Cardiology, Civil Hospital Marie Curie, Charleroi, Belgium.
LANCELLOTTI, Patrizio ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
Mairesse, Georges H ; Department of Cardiology, Cliniques du Sud-Luxembourg, Arlon, Belgium.
de Veer, Anne ; Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Casado Arroyo, Ruben; Department of Cardiology, Hospital Erasme, Anderlecht, Belgium.
Catez, Emmanuel ; Department of Cardiology, Brugmann University Hospital, Brussels, Belgium.
de Pauw, Michel ; Department of Cardiology, Ghent University Hospital, Ghent, Belgium.
Vanassche, Thomas ; Department of Cardiology, Leuven University Hospital, Leuven, Belgium.
de Asmundis, Carlo ; Department of Cardiology, University Hospital Brussels, Brussels, Belgium.
Kirchhof, Paulus ; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. ; The Atrial Fibrillation NETwork (AFNET), Münster, Germany.
De Caterina, Raffaele ; Department of Cardiology, University of Pisa, Pisa, Italy.
de Groot, Joris R ; Department of Cardiology, Amsterdam Medical Centres/University of Amsterdam
ETNA-AF-Europe principal investigators from Belgium and the, Netherlands
Beyer-Westendorf J, Camm AJ, Fox KAA, et al.; RIVER Registry Investigators. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: rivaroxaban evaluation in real life setting (river). Thromb J. 2019; 17: 7.
Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361 (12): 1139–1151.
Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369 (22): 2093–2104.
Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365 (11): 981–992.
Halvorsen S, Ghanima W, Fride Tvete I, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017; 3 (1): 28–36.
Hohnloser SH, Basic E, Hohmann C, et al. Effectiveness and safety of non-vitamin k oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost. 2018; 118 (3): 526–538.
Martinez CAA, Lanas F, Radaideh G, et al.; XANTUS Investigators. Xantus-el: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. Egypt Heart J. 2018; 70 (4): 307–313.
Maura G, Billionnet C, Drouin J, et al. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin k antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016. BMJ Open. 2019; 9 (4): e026645.
Mazurek M, Huisman MV, Rothman KJ, et al.; GLORIA-AF Investigators. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the gloria-af phase ii registry. Thromb Haemost. 2017; 117 (12): 2376–2388.
Mueller T, Alvarez-Madrazo S, Robertson C, et al. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. Br J Clin Pharmacol. 2019; 85 (2): 422–431.
Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365 (10): 883–891.
Pottegard A, Grove EL, Hellfritzsch M., Use of direct oral anticoagulants in the first year after market entry of edoxaban: a Danish nationwide drug utilization study. Pharmacoepidemiol Drug Saf. 2018; 27 (2): 174–181.
Steinberg BA, Gao H, Shrader P, et al.; ORBIT-AF Investigators. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the garfield-af, orbit-af i, and orbit-af ii registries. Am Heart J. 2017; 194: 132–140.
Vinogradova Y, Coupland C, Hill T, et al. Risks and benefits of direct oral anticoagulants vs warfarin in a real world setting: cohort study in primary care. BMJ. 2018; 362: 2505.
Lixiana: Epar–product information. European Medicines Agency; 2015 [Updated 2019 Jul 10, Accessed 2019 Aug 28]. https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf
De Caterina R, Kelly P, Monteiro P, et al.; ETNA-AF-Europe investigators. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (af) in Europe (ETNA-AF-Europe). BMC Cardiovasc Disord. 2019; 19 (1): 165.
De Caterina R, Kelly P, Monteiro P, et al.; ETNA-AF-Europe investigators. Design and rationale of the edoxaban treatment in routine clinical practice for patients with atrial fibrillation in Europe (ETNA-AF-Europe) study. J Cardiovasc Med (Hagerstown). 2019; 20 (2): 97–104.
Hanemaaijer S, Sodihardjo F, Horikx A, et al. Trends in antithrombotic drug use and adherence to non-vitamin k oral anticoagulants in the Netherlands. Int J Clin Pharm. 2015; 37 (6): 1128–1135.
van den Heuvel JM, Hovels AM, Buller HR, et al. Noacs replace vka as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in the Netherlands. Thromb J. 2018; 16: 7.
Moudallel S, Steurbaut S, Cornu P, et al. Appropriateness of doac prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing. Front Pharmacol. 2018; 9: 1220.
Santos J, Antonio N, Rocha M, et al. Impact of direct oral anticoagulants off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. Br J Clin Pharmacol. 2020; 86 (3): 533–547.
Arbel R, Sergienko R, Hammerman A, et al. Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am J Med. 2019; 132 (7): 847–855.e843.
Steinberg BA, Shrader P, Pieper K, et al. Frequency and outcomes of reduced dose non-vitamin k antagonist anticoagulants: results from orbit-af ii (the outcomes registry for better informed treatment of atrial fibrillation ii). J Am Heart Assoc. 2018; 7 (4): pii: e007633.
Yao X, Shah ND, Sangaralingham LR, et al. Non-vitamin k antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017; 69 (23): 2779–2790.
Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-factor xa activity, and outcomes: an analysis of data from the randomised, double-blind engage af-timi 48 trial. Lancet. 2015; 385 (9984): 2288–2295.
Stacy ZA, Call WB, Hartmann AP, et al. Edoxaban: a comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism. Cardiol Ther. 2016; 5 (1): 1–18.
Kirchhof P, Benussi S, Kotecha D, et al.; ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37 (38): 2893–2962.
Steffel J, Verhamme P, Potpara TS, et al.; ESC Scientific Document Group. The 2018 European heart rhythm association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39 (16): 1330–1393.
Tjin-A-Tsoi TBPM., The Netherlands on a European scale 2019. Statistics Netherlands (CBS). 2019 [accessed 28 Feb 2020]. https://longreads.cbs.nl/european-scale-2019/
